Alto Neuroscience, Inc. (NYSE:ANRO)
Health Care/Life Sciences • Biotechnology
CIK 1999480
Company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
Address
650 Castro Street
Suite 450
Mountain View, California 94041
650 Castro Street
Suite 450
Mountain View, California 94041
Employees
63
63
Stock Info
Close
$3.3800
$3.3800
Day Range
3.1999 - 3.5550
3.1999 - 3.5550
52 Week Range
2.6700 - 18.3499
2.6700 - 18.3499
Average volume
305.83K
305.83K
Short Interest
3.98M (02/14/25)
3.98M (02/14/25)
% of Float Shorted
17.30%
17.30%
Market Cap
$91.16M
$91.16M
Revenue
N/A
N/A
Net Income
-$36.31M
-$36.31M
2020 Sales Growth
N/A
N/A
Key Executives
Board Of Directors
|
Chairman, President & Chief Executive Officer Amit Etkin |
|
Director Po Yu Chen |
|
Director Husseini K. Manji |
|
Lead Independent Director Christopher Nixon Cox |
|
Independent Director Andrew Dreyfus |
|
Independent Director Gwill E. York |
|
Independent Director Mahalakshmi Radhakrishnan |
SEC filings
| Date | Form | Event |
|---|---|---|
| 14 Nov, 2024 | SC 13G | |
| 14 Nov, 2024 | SC 13G/A | |
| 12 Nov, 2024 | SC 13G | |
| 12 Nov, 2024 | 10-Q | |
| 12 Nov, 2024 | 8-K | |
| 8 Nov, 2024 | SC 13G | |
| 22 Oct, 2024 | 8-K | |
| 21 Oct, 2024 | SC 13G | |
| 13 Aug, 2024 | 8-K | |
| 13 Aug, 2024 | 10-Q | |
| 29 Jul, 2024 | 8-K | |
| 11 Jul, 2024 | 4 | |
| 22 May, 2024 | 4 | |
| 22 May, 2024 | 3 | |
| 21 May, 2024 | 8-K | |
| 14 May, 2024 | 10-Q | |
| 14 May, 2024 | 8-K | |
| 1 Apr, 2024 | 4 | |
| 29 Mar, 2024 | SC 13G | |
| 21 Mar, 2024 | 8-K | |
| 21 Mar, 2024 | 10-K | |
| 12 Mar, 2024 | 4 | |
| 12 Mar, 2024 | 3 | |
| 11 Mar, 2024 | 8-K | |
| 6 Mar, 2024 | 4 | |
| 5 Mar, 2024 | 4 | |
| 5 Mar, 2024 | 4 | |
| 5 Mar, 2024 | 4 | |
| 9 Feb, 2024 | SC 13G | |
| 8 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | 4 | |
| 7 Feb, 2024 | SC 13G | |
| 7 Feb, 2024 | 4 | |
| 6 Feb, 2024 | 8-K | |
| 6 Feb, 2024 | S-8 | |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 4 | |
| 5 Feb, 2024 | 424B4 | IPO completed |
| 5 Feb, 2024 | 4 | |
| 2 Feb, 2024 | 3 | |
| 2 Feb, 2024 | SEC STAFF | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | EFFECT | |
| 1 Feb, 2024 | S-1MEF | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 1 Feb, 2024 | 3 | |
| 30 Jan, 2024 | CERT | |
| 30 Jan, 2024 | 8-A12B | |
| 30 Jan, 2024 | CORRESP | |
| 30 Jan, 2024 | CORRESP | |
| 29 Jan, 2024 | S-1/A | |
| 29 Jan, 2024 | S-1/A | |
| 25 Jan, 2024 | CORRESP | |
| 24 Jan, 2024 | CORRESP | |
| 23 Jan, 2024 | UPLOAD | |
| 19 Jan, 2024 | CORRESP | |
| 12 Jan, 2024 | S-1 | |
| 12 Jan, 2024 | CORRESP | |
| 9 Jan, 2024 | UPLOAD | |
| 9 Jan, 2024 | SEC STAFF | |
| 28 Dec, 2023 | DRS/A | |
| 28 Dec, 2023 | DRSLTR | |
| 19 Dec, 2023 | UPLOAD | |
| 27 Nov, 2023 | D | |
| 27 Nov, 2023 | D | |
| 27 Nov, 2023 | D | |
| 27 Nov, 2023 | D | |
| 22 Nov, 2023 | DRS |
Last update:2025-03-06 12:07:16.430098
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.